Trial Profile
A Multicenter, Open Label Trial Evaluating Intravenous Azithromycin Plus Intravenous Ampicillin/Sulbactam Followed by Oral Azithromycin Plus Intravenous Ampicillin/Sulbactam for the Treatment of Hospitalized Subjects With Community-Acquired Pneumonia (CAP)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Sep 2014
Price :
$35
*
At a glance
- Drugs Ampicillin/sulbactam (Primary) ; Azithromycin (Primary)
- Indications Community-acquired pneumonia
- Focus Therapeutic Use
- Sponsors Pfizer
- 29 Sep 2014 New trial record